1Kruger S, Graf J, Merx MW, et al. Brain natriuretic peptide predicts right heart failure in patients with acute pulmonaryem bolism[J]. Am Heart J,2004,147(1):60-65.
2Leroy G, Uzan L, Bugugnani MG, et al. The value of repeated determinations of brain natriuretic peptide for the diagnosis of unstable angina[J]. Arch Mal Coeur Vaiss,2003,96(4):305-310.
3Tokola H, Hautala N, Marttila M, et al. Mechanical load-induced alterations in B-type natfiuretic peptide gene expression[J]. Can J Physiol Pharmacol, 2001,79(8):646-653.
4Mir TS, Marohn S, Laer S, et al. Plasma concentrations of Nterminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure[J]. Pediatrics, 2002,110(6):76-87.
5Koch A, Singer H. Normal values of B type natriuretic peptide in infants, children, and adolescents[J]. Heart,2003,89(8):875-878.
7Ohuchi H, Takasugi H, Ohashi H, et al. Stratification of pediatric heart failure on the basis of neurohormonal and cardiac autonomic nervous activities in patients with congenital heart disease[J]. Circulation, 2003.308(19):2368-2376.
8Morrison LK, Harrison A, Kfishnaswamy P, et al. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea[J]. J Am Coil Cardiol,2002,39(2):202-209.
9Lubien E, DeMaria A, Krishnaswamy P, et al. Utility of Bnatriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings[J]. Circulation, 2002,105(5):595-601.
10Laer S, Mir TS, Behn F, et al. Carvedilol therapy in peditric patients with congestive heart failure: a study investi-gating clinical and pharmacokinetic parameters[J]. Am Heart J,2002,143(5):916-922.
2Suda K, Matsumura M, Matsumoto M. Clinical implication of plasma natriuretic peptides in children with ventricular septal defect. Pediatr Int, 2003, 45(3) :249 - 254.
3Mir T, Stephani S, Eiselt M, et al. Plasma concentration of N-terminal pro-brain natriurtic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics,2002, 110(6):e76- 87.
4Kawai K, Hata K, Takaoka H, et al. Plasma brain natriuretic peptide as a noval therapetic indicator in idiopathic dilated cardiomyopathy during β-blocker therapy: a potential of hormone-guided treatment. Am Heart J, 2001, 141(6) :925 - 932.
5Hirata Y, Matsumoto A, Aoyagi T, et al. Measurement of plasma brain natriuretic peptide level as a gudie for cardiac overload. Cardiovasc Res, 2001, 51:585 - 591.
6Kirkwood F, Vandana S, Mihai G, et al. B-Type natriuretic peptide: from bench to bedside. Am Heart J,2003, 145(2) :S34- 46.
7Kinnunen P, Vuolteenaho O, Ruskoaho H, et al. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium:effect of stretching. Endocrinology, 1993, 132(5) :1961- 1970.
8Ikeda T, Matsuda K, Itoh H, et al. Plasma levels of brain and atrial natriuretic peptides elevate in proportion to left ventricular end-systolic wall stressin patients with aortic stenosis. Am Heart J, 1997, 133(3):307- 314.
9Colann SD, Borow KM, Neumann A. Left ventricular end-systolic wall stress-velocity of fiber shortening relation: a load-independent index of myocardial contractility. J Am Coll Cardiol, 1984, 4(3) :715- 721.
10Kimball T, Daniels S, Meyer R, et al. Relation of symptoms to contractility and defect size in infants with ventricular septal defect. Am J Cardiol, 1991, 67(3) :1097- 1102.
